Neoadjuvant chemotherapy and pathologic response: a retrospective cohort

Diocésio Alves Pinto de Andrade, Gustavo Zucca-Matthes, René Aloísio da Costa Vieira, Cristiane Thomaz de Aquino Exel de Andrade, Allini Mafra da Costa, Aurélio Julião de Castro Monteiro, Lissandra Dal Lago, João Soares Nunes

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)


OBJECTIVE: To evaluate the complete pathologic response attained by patients diagnosed with locally advanced breast cancer submitted to neoadjuvant chemotherapy based on the doxorubicin/cyclophosphamide regimen followed by paclitaxel.

METHODS: A retrospective cohort of patients with locally advanced breast cancer, admitted to the Hospital de Câncer de Barretos between 2006 and 2008 submitted to the doxorubicin/cyclophosphamide protocol followed by paclitaxel (4 cycles of doxorubicin 60mg/m² and cyclophosphamide 600mg/m² every 21 days; 4 cycles of paclitaxel 175mg/m² every 21 days). The following variables were assessed: age, menopause, performance status, initial clinical staging, anthropometric data, chemotherapy (dose - duration), toxicity profile, post-treatment staging, surgery, pathologic complete response rate, disease-free survival, and pathological characteristics (type and histological degree, hormonal profile and lymph node involvement). Statistical analysis was performed using a 5% level of significance.

RESULTS: Of the 434 patients evaluated, 136 were excluded due to error in staging or because they had received another type of chemotherapy. Median age was 50 years, all with performance status 0-1. Median initial clinical size of tumor was 65mm and the median final clinical size of the tumor was 22mm. Fifty-one (17.1%) patients experienced a pathologic complete response. Those with a negative hormonal profile or who were triple-negative (negative Her-2 and hormonal profile) experienced a favorable impact on the pathologic complete response.

CONCLUSION: Neoadjuvant chemotherapy with doxorubicin/cyclophosphamide followed by paclitaxel provided a pathologic complete response in the population studied in accordance with that observed in the literature. Triple-negative patients had a greater chance of attaining this response.

Original languageEnglish
Pages (from-to)446-50
Number of pages5
JournalEinstein (São Paulo, Brazil)
Issue number4
Publication statusPublished - Dec 2013
Externally publishedYes


  • Adult
  • Aged
  • Antineoplastic Agents, Alkylating/administration & dosage
  • Antineoplastic Agents, Phytogenic/administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols/administration & dosage
  • Breast Neoplasms/drug therapy
  • Cohort Studies
  • Cyclophosphamide/administration & dosage
  • Doxorubicin/administration & dosage
  • Female
  • Humans
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Paclitaxel/administration & dosage
  • Retrospective Studies
  • Treatment Outcome
  • Young Adult


Dive into the research topics of 'Neoadjuvant chemotherapy and pathologic response: a retrospective cohort'. Together they form a unique fingerprint.

Cite this